Esophageal Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major esophageal squamous cell carcinoma markets are expected to exhibit a CAGR of 8.1% during 2024-2034.
The esophageal squamous cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Esophageal Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Esophageal squamous cell carcinoma refers to a type of tumor that originates in the thin, flat cells lining the esophagus, which is the muscular tube that delivers food from the throat to the stomach. This condition often causes narrowing of the esophagus due to tumor growth, resulting in difficulty swallowing. Individuals suffering from the ailment may experience a burning sensation in the chest or throat, unexplained weight loss, lack of appetite, blood in the vomit, persistent cough, hoarseness or changes in voice, heartburn, indigestion, regurgitation of food or liquid, generalized fatigue, weakness, etc. The diagnosis of esophageal squamous cell carcinoma typically involves a combination of medical history evaluation, clinical feature assessment, physical examination, and pathological analysis. An endoscopy, which uses a flexible tube with a light and camera to visualize the inside of the esophagus and identify any abnormalities, is also recommended for patients. The healthcare provider may further perform various diagnostic procedures, such as barium swallow tests, positron emission tomography (PET) scans, X-rays, etc., to obtain cross-sectional images of the affected regions.
The increasing cases of inherited gene mutations, which can cause alteration in detoxification pathways or DNA repair mechanisms, are primarily driving the esophageal squamous cell carcinoma market. In addition to this, the rising prevalence of numerous associated risk factors, like excessive tobacco and alcohol use, exposure to harmful chemicals and irritants, an unhealthy diet, gastroesophageal reflux disease, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, which are designed specifically to target cancerous cells or specific molecules that are responsible for tumor progression, is further bolstering the market growth. Apart from this, the escalating application of radiofrequency ablation procedures, on account of their numerous advantages, such as less trauma to the patient, reduced pain, quicker recovery compared to traditional open surgeries, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of endoscopic mucosal resection, since it targets the abnormal mucosal layers and aims to remove the cancerous tissue while preserving the function and structure of the esophagus, is expected to drive the esophageal squamous cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the esophageal squamous cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for esophageal squamous cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the esophageal squamous cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the esophageal squamous cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the esophageal squamous cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current esophageal squamous cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Merformance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the esophageal squamous cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the esophageal squamous cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the esophageal squamous cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of esophageal squamous cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal squamous cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal squamous cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with esophageal squamous cell carcinoma across the seven major markets?
What is the size of the esophageal squamous cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of esophageal squamous cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Esophageal Squamous Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for esophageal squamous cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the esophageal squamous cell carcinoma market?
What are the key regulatory events related to the esophageal squamous cell carcinoma market?
What is the structure of clinical trial landscape by status related to the esophageal squamous cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the esophageal squamous cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the esophageal squamous cell carcinoma market?
The esophageal squamous cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Esophageal Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Esophageal squamous cell carcinoma refers to a type of tumor that originates in the thin, flat cells lining the esophagus, which is the muscular tube that delivers food from the throat to the stomach. This condition often causes narrowing of the esophagus due to tumor growth, resulting in difficulty swallowing. Individuals suffering from the ailment may experience a burning sensation in the chest or throat, unexplained weight loss, lack of appetite, blood in the vomit, persistent cough, hoarseness or changes in voice, heartburn, indigestion, regurgitation of food or liquid, generalized fatigue, weakness, etc. The diagnosis of esophageal squamous cell carcinoma typically involves a combination of medical history evaluation, clinical feature assessment, physical examination, and pathological analysis. An endoscopy, which uses a flexible tube with a light and camera to visualize the inside of the esophagus and identify any abnormalities, is also recommended for patients. The healthcare provider may further perform various diagnostic procedures, such as barium swallow tests, positron emission tomography (PET) scans, X-rays, etc., to obtain cross-sectional images of the affected regions.
The increasing cases of inherited gene mutations, which can cause alteration in detoxification pathways or DNA repair mechanisms, are primarily driving the esophageal squamous cell carcinoma market. In addition to this, the rising prevalence of numerous associated risk factors, like excessive tobacco and alcohol use, exposure to harmful chemicals and irritants, an unhealthy diet, gastroesophageal reflux disease, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, which are designed specifically to target cancerous cells or specific molecules that are responsible for tumor progression, is further bolstering the market growth. Apart from this, the escalating application of radiofrequency ablation procedures, on account of their numerous advantages, such as less trauma to the patient, reduced pain, quicker recovery compared to traditional open surgeries, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of endoscopic mucosal resection, since it targets the abnormal mucosal layers and aims to remove the cancerous tissue while preserving the function and structure of the esophagus, is expected to drive the esophageal squamous cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the esophageal squamous cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for esophageal squamous cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the esophageal squamous cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the esophageal squamous cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the esophageal squamous cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current esophageal squamous cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Merformance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the esophageal squamous cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the esophageal squamous cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the esophageal squamous cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of esophageal squamous cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal squamous cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal squamous cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with esophageal squamous cell carcinoma across the seven major markets?
What is the size of the esophageal squamous cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of esophageal squamous cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Esophageal Squamous Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for esophageal squamous cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the esophageal squamous cell carcinoma market?
What are the key regulatory events related to the esophageal squamous cell carcinoma market?
What is the structure of clinical trial landscape by status related to the esophageal squamous cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the esophageal squamous cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the esophageal squamous cell carcinoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - UNMET NEEDS
10 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Esophageal Squamous Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Esophageal Squamous Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Tislelizumab - BeiGene
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Durvalumab - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ESOPHAGEAL SQUAMOUS CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ESOPHAGEAL SQUAMOUS CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Esophageal Squamous Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Esophageal Squamous Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Esophageal Squamous Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Esophageal Squamous Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Esophageal Squamous Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Esophageal Squamous Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Esophageal Squamous Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Esophageal Squamous Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
16 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - UNMET NEEDS
10 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Esophageal Squamous Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Esophageal Squamous Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Tislelizumab - BeiGene
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Durvalumab - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ESOPHAGEAL SQUAMOUS CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ESOPHAGEAL SQUAMOUS CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Esophageal Squamous Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Esophageal Squamous Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Esophageal Squamous Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Esophageal Squamous Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Esophageal Squamous Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Esophageal Squamous Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Esophageal Squamous Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Esophageal Squamous Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Esophageal Squamous Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Esophageal Squamous Cell Carcinoma - Access and Reimbursement Overview
16 ESOPHAGEAL SQUAMOUS CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
